Sanofi/Regeneron's Zaltrap fails in third oncology indication - prostate cancer
This article was originally published in Scrip
Executive Summary
Sanofi and Regeneron's Zaltrap (aflibercept) has failed to meet the primary endpoint in the Phase III VENICE trial for the first-line treatment of metastatic androgen-independent prostate cancer, top-line results show. This is the third oncology indication in which the drug has failed.